Introduction to a review series on mantle cell lymphoma: sands shifting in the darkness

Abstract

Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin B-cell lymphoma that defies cures in most patients. Over the last decade, significant advances have been made in our understanding of the biology of the disease, patient risk stratification, and novel therapies. Associate Editor Philippe Armand presents a series of reviews that provide advice on management of patients, illuminate current understanding of the molecular landscape associated with the disease, and how that may shape future research and care. Ryan et al review the current frontline management of MCL in a rapidly evolving field, underscoring ongoing phase 3 trials; Silkenstedt and Dreyling highlight the emerging treatments for relapsed and refractory MCL; Jain and Wang tackle the critical issue of risk assignment based on clinical and molecular features; and Sarkozy and colleagues explore in depth the biology of MCL with an emphasis not only on intrinsic vulnerabilities but also on the tumor microenvironment.